Dutch Startup Secures $70 Million to Replace Human Blood Draws with AI Robots
Netherlands, Thursday, 12 March 2026.
Vitestro’s breakthrough funding round positions autonomous blood-drawing technology as the solution to healthcare’s staffing crisis. Their Aletta robot achieves a remarkable 95% first-stick success rate using AI and multimodal imaging to locate veins and collect samples without human intervention. The technology addresses billions of annual blood draws worldwide, with major healthcare investors including Mayo Clinic and Labcorp betting on robots transforming routine medical procedures.
Healthtech Innovation Addresses Critical Healthcare Staffing Crisis
This development represents a significant advancement in healthtech innovation, specifically targeting one of healthcare’s most pressing challenges. Vitestro, a Netherlands-based medical technology company, announced on March 10, 2026, that it secured $70 million in an oversubscribed Series B financing round [1][2]. The funding round attracted notable strategic investors including Labcorp Venture Fund, Mayo Clinic, and Sutter Health, alongside financial investors InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht [2][3]. Existing investors Invest-NL, EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital continued their support in this round [2][3]. Toon Overbeeke, Chief Executive Officer and co-founder of Vitestro, stated that “Closing our Series B financing reflects strong conviction in our mission to establish a new standard in autonomous robotic venous access and diagnostic blood collection” [1][2][3].
Revolutionary Technology Behind Autonomous Blood Collection
The company’s flagship innovation, the Aletta Autonomous Robotic Phlebotomy Device (ARPD), represents a breakthrough in medical robotics technology. The system combines multimodal imaging, advanced robotics, and artificial intelligence to identify suitable veins, guide needle insertion, and collect blood samples with high precision and consistency [2][3][4]. The technology utilizes ultrasound to locate suitable veins, while a robotic arm positions the needle with extreme precision to draw blood from patients [7]. The system can also switch blood collection tubes and apply bandages after procedures [7]. Notably, the device achieved a 95% first-stick success rate in clinical trials and has already received CE mark approval in Europe [1]. The technology addresses what Overbeeke describes as “the highest-volume invasive medical procedure globally, with billions of procedures performed annually” [1][2].
Strategic Market Positioning and Commercial Rollout Plans
Vitestro’s commercial strategy focuses on addressing critical workforce shortages in healthcare systems worldwide. The funding will enable the company to advance the Aletta platform, conduct further clinical studies, scale manufacturing operations, and prepare for broader deployment across hospitals and laboratories [1][2][3]. The commercial rollout will begin in the Netherlands at hospitals participating in clinical trials, followed by broader European expansion with Denmark identified as the first international market [7]. Simultaneously, the company is pursuing U.S. FDA De Novo regulatory pathway approval to enter the American market [2][3][4]. Dr. Fred Moll, co-founder and partner at Sonder Capital and former co-founder and CEO of Intuitive Surgical and Auris Health, emphasized that “Vitestro is redefining one of the largest and most under innovated clinical workflows with a first-of-its-kind autonomous robotic platform for diagnostic blood collection addressing an enormous unmet global market need” [2][3].
Industry Impact and Future Healthcare Transformation
The investment reflects growing confidence in autonomous healthcare technologies and their potential to transform traditional medical workflows. Megann Vaughn Watters, Head of Labcorp Venture Fund, noted that “The Labcorp Venture Fund sees strong potential in solutions that modernize core diagnostic processes and improve consistency for patients” [3][4]. The technology is designed to support phlebotomy departments by performing routine diagnostic blood draws, helping address staffing challenges, reduce human-dependent variability, standardize quality, and enhance the overall patient experience [4]. Dr. Moll compared the potential impact to early robotic surgery developments, stating “I believe this technology has the potential to establish a new standard of care, much as robotic surgery did in its early days” [3]. The Aletta system is currently deployed in clinical and pre-commercial settings in Europe but awaits FDA authorization for U.S. market entry [2].